• Case-Based Modules
• Hepatitis A
• Hepatitis B
• Hepatitis C
• Common Management Issues
• Health Educator
• Home

Monitoring and Management of Patients on Therapy for Chronic Hepatitis B

You answered:

After starting therapy, the patient should have his ALT and HBV DNA level next measured at the end of 1 year of therapy.

This answer is incorrect. According to AASLD guidelines, all patients on therapy for HBV should have a liver panel measured every 3 months and HBV DNA levels quantified every 3 to 6 months. The frequency of HBV DNA monitoring is to assure an initial response to therapy and that any antiviral resistance is picked up early.

Choose another answer:

	For HBeAg-positive patients, monitoring for HBeAg seroconversion should occur only after the patient has achieved HBsAg seroconversion.
	As soon as the patient obtains an undetectable HBV DNA level, it is advisable for him to stop therapy.
	If the patient’s HBV DNA level declines by 1 log10 after 6 months of therapy, the response is termed a primary non-response.

[Back to Question | Go to Correct Answer]